6185.HK CanSino Biologics Inc
Performance
-11.84% Past Week
Market Cap
10.36B
Day’s Range
52W Range
Volume (3M)
1.57M
Price-Earnings Ratio
-10.21
Revenue
1.21B
About CanSino Biologics Inc
CanSino Biologics Inc. is a biotechnology and biopharmaceuticals company based in the People’s Republic of China. Originally founded in 2009, CanSino Biologics is primarily focused on the clinical stage vaccine market segment. The company has an international focus in terms of distribution and is currently headquartered in Tianjin in the People’s Republic of China.
CanSino Biologics Inc. is listed on the Hong Kong Stock Exchange (HKEX) under the 6185.HK ticker. In terms of the performance of the 6185.HK share price, Cansino Biologics Inc. has posted a 52-week high of 285.20 HKD to a 52-week low of 32.90 HKD. It has been traded on the HKEX since it was first listed in July 2018.
CanSino Biologics Inc.’s main commercial interests lie in the development and manufacture of vaccines. Some of its most high-profile vaccines include an Ebola virus vaccine, as well as vaccines for the prevention of N. meningitides. In 2020, CanSino Biologics Inc. signed a collaboration agreement with The National Research Council of Canada and Precision NanoSystems Inc. to develop vaccines to combat COVID-19. It was one of the first companies to secure a patent for its COVID-19 vaccine in China.
To keep up to date with the latest news, updates, and financial data on the CanSino Biologics Inc. stock, simply add the 6185.HK ticker to your eToro watchlist.
Show More2.2K
Employees
HK
HQ
2009
Founded
Xue Feng Yu, PhD
CEO
Upcoming Earnings
27
APR
REPORTS
CanSino Biologics Inc Q1 2023 earnings report is expected to be released after market open
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
59
High
Industry
Avg. 45
60
Environment
71
Social
46
Governance
People Also Bought
41.99